Uccle

Glioblastoma (GBM) is the most common and aggressive brain tumor, affecting about 600 patients annually in Belgium. Despite treatments including surgery, radiotherapy, and chemotherapy, survival remains limited, with most patients living 12-18 months and only 5% surviving beyond 5 years. The BELGICA trial aims to determine if a more focused radiotherapy approach can reduce side effects and improve quality of life for patients with GBM. This trial compares two radiotherapy approaches: one with a smaller clinical target volume (CTV) margin of 10mm and the other with the standard margin of 15mm around the tumor or tumor bed. Reducing the CTV margin is expected to decrease the amount of healthy brain tissue exposed to radiation, potentially lowering treatment toxicity without compromising tumor control. Participants will be monitored from randomization until the study ends to assess overall survival. Researchers will also evaluate treatment side effects and quality of life. Eligibility requires adults with newly diagnosed glioblastoma who are suitable for chemoradiotherapy. Assessments include clinical evaluations and MRI scans, while safety and side effects are carefully tracked throughout the study.